[The Evolution of Diabetes Treatment: Combining Innovative Pharmacological Therapies and Advanced Devices toward
Jong Han Choi1, Min Kyong Moon2
1건국대학교 의과대학/의학전문대학원 내과학교실.
Abstract:
The global prevalence of diabetes is rapidly increasing, with one in six adults in the Republic of Korea being affected. Traditional diabetes management focuses on glycemic control to prevent complications. However, recent advancements emphasize individualized treatment strategies. These involve using drugs with a low risk of hypoglycemia and the potential to prevent various metabolic diseases, aiming for diabetes remission, or selecting medications based on comorbidities, regardless of blood glucose levels. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists not only improve glycemic control but also offer cardiovascular and renal protective effects, making them direct therapeutic options for these conditions. Additionally, early combination therapy, involving medications with different mechanisms of action from those used in the early stages of diabetes, is being increasingly promoted to minimize treatment failure and reduce diabetes-related complications. Innovations in diabetes management devices, including continuous glucose monitoring systems, smart insulin pens, and automated insulin delivery systems, have improved glucose control accuracy and enhanced treatment adherence. For type 1 diabetes, novel therapies, such as once-weekly basal insulin and immunotherapies, have been introduced, with various approaches targeting autoimmune responses currently under investigation. This study explored the impact of these emerging therapeutic agents and management devices on diabetes care and presented future prospects for advancing diabetes remission, based on recent research trends.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes: Symptoms, Diagnosis, and Complications
Drug Therapy
Antianxiety Medications


